key: cord-0991032-r9xi5br5
authors: Favà, Alexandre; Donadeu, Laura; Jouve, Thomas; Gonzalez-Costello, José; Lladó, Laura; Santana, Carolina; Toapanta, Néstor; Lopez, Manuel; Pernin, Vincent; Facundo, Carme; Cabañas, Nuria Serra; Thaunat, Olivier; Crespo, Marta; Llinàs, Laura; Revuelta, Ignacio; Sabé, Nuria; Rombauts, Alexander; Calatayud, Laura; Ardanuy, Carmen; Esperalba, Juliana; Fernandez, Candela; Lozano, Juan J.; Preyer, Rosemarie; Strecker, Kevin; Couceiro, Carlos; García-Romero, Elena; Cachero, Alba; Meneghini, Maria; Torija, Alba; Le Quintrec, Moglie; Melilli, Edoardo; Cruzado, Josep Maria; Polo, Carolina; Moreso, Francesc; Crespo, Elena; Bestard, Oriol
title: A comprehensive assessment of long-term SARS-CoV-2-specific adaptive immune memory in convalescent COVID-19 Solid Organ Transplant recipients
date: 2022-02-04
journal: Kidney Int
DOI: 10.1016/j.kint.2021.12.029
sha: cab237dfb6bb60ed819847ef60700c7fff7c6925
doc_id: 991032
cord_uid: r9xi5br5

Long-term adaptive immune memory has been reported among immunocompetent individuals up to eight months following SARS-CoV-2 infection. However, limited data is available in convalescent patients with a solid organ transplant. To investigate this, we performed a thorough evaluation of adaptive immune memory at different compartments (serological, memory B cells and cytokine [IFN-γ, IL-2, IFN-γ/IL2 and IL-21] producing T cells) specific to SARS-CoV-2 by ELISA and FluoroSpot-based assays in 102 convalescent patients (53 with a solid organ transplants (38 kidney, 5 liver, 5 lung and 5 heart transplant) and 49 immunocompetent controls) with different clinical COVID-19 severity (severe, mild and asymptomatic) beyond six months after infection. While similar detectable memory responses at different immune compartments were detected between those with a solid organ transplant and immunocompetent individuals, these responses were predominantly driven by distinct COVID-19 clinical severities (97.6%, 80.5% and 42.1%, all significantly different, were seropositive; 84% vs 75% vs 35.7%, all significantly different, showed IgG-producing memory B cells and 82.5%, 86.9% and 31.6%, displayed IFN-γ producing T cells; in severe, mild and asymptomatic convalescent patients, respectively). Notably, patients with a solid organ transplant with longer time after transplantation did more likely show detectable long-lasting immune memory, regardless of COVID-19 severity. Thus, our study shows that patients with a solid organ transplant are capable of maintaining long-lasting peripheral immune memory after COVID-19 infection; mainly determined by the degree of infection severity.

associates with an excessive systemic inflammatory process, ultimately leading to respiratory failure and death. 3, 4 Notably, some specific group of patients seem to be at significantly higher risk of fatal outcomes such as recipients of solid organ transplants (SOT), most likely due to their chronic immunosuppressive therapy that broadly targets adaptive T-cell immunity. 5, 6 Recent important studies have shown that during acute COVID-19 and early convalescence, infected patients develop robust adaptive immune responses by means of high SARS-CoV-2-specific IgG antibody titers and T-cell frequencies, both CD4 and CD8 T cells, in peripheral blood. 7 Remarkably, the strength of these adaptive immune responses seems to also vary according to distinct COVID-19 disease severity 8, 9, 10, 11, 12 thus, suggesting a key role of SARS-CoV-2-specific immunity controlling and limiting primary viral. 13, 14, 15, 16 On the other hand, a long-lasting protective immunity, both serological and cellular, has also been reported among convalescent COVID-19 patients from the general population between 5 and 8 months after infection. 17 In the setting of SOT, however, scarce information has been reported regarding the degree, durability and biological interplay between different adaptive immune mechanisms in response to SARS-CoV-2. In this regard, our group recently showed that SOT patients developing a moderate/severe COVID-19 infection are able to J o u r n a l P r e -p r o o f

One-hundred and two COVID- 19 March/October 2020. Samples from 16 pre-pandemic uninfected individuals were used as negative controls for T cell assays, as described elsewhere 18 . Additional 10 historic biological samples were employed as a controls for the B cell functional assays.

As shown in the flow-chart of the study (Figure 1) The study was approved by the Ethical Review Boards (PR115/20) at each center and patients were recruited in the study after providing a signed informed consent.

Detailed description is depicted in supplementary methods.

Serum IgG antibodies were assessed against two main SARS-CoV-2 antigens: the Nucleoprotein and Spike glycoprotein in 101/102 (99%) study patients using two distinct ELISA platforms. Detailed information of the methodology and interpretation is provided as supplementary material.

Circulating SARS-CoV-2-specific IgG-producing memory B-cell (mBC) frequencies 

Continuous variables were expressed as mean ± SD or median and IQR and categorical variables as number of total (n) and percentage (%). A comparison between groups was performed using Pearson' χ2 test for categorical data.

Continuous measurements were compared among groups using Kruskal-Wallis and J o u r n a l P r e -p r o o f

As shown in the study flow-chart ( Figure 1 ) and median days, p=0.005) than SOT (Figure 1 ) and these differences were mainly driven by the MILD IC group, which was composed of healthcare workers ( Table 1) . Among the remaining groups, IC and SOT were matched for age and time after infection.

There were no differences regarding the type of immunosuppression, SOT or time after transplantation between the 3 distinct clinical groups.

None of the included patients was diagnosed of transplant rejection during the acute SARS-CoV-2 infection or the follow-up, but one kidney transplant individual who presented a sub-clinical antibody mediated rejection in a 12-month protocol biopsy.

As illustrated in an unsupervised heatmap in 4d ).

Overall, there were no differences regarding the proportion of patients with detectable SARS-CoV-2-reactive T cells or their frequencies for any of the evaluated cytokine-

A hierarchical T-cell immune response was observed that was mainly dominated by Of note, a less pronounced SARS-CoV-2-specific T-cell gradient was observed among SOT as compared to IC patients, especially between severe and mild convalescent COVID-19 patients.

A significant positive correlation between serum IgG titers and frequencies of IgG and cytokine-producing memory B and T cells, respectively, against protein S was observed, which was more robustly observed within the IC group (Figure 7) .

Conversely, no correlation was found between serologic and cellular responses against protein N and between frequencies of IgG-producing mBC and cytokineproducing T cells. Notably, a significant decline was observed in all cytokine-producing SARS-CoV-2reactive T-cell frequencies but not in IL-21, in both groups (Figure 9b) , with a higher proportion of SOT becoming non T-cell responders than IC (Figure 9c ).

We then investigated whether main demographic characteristics such as age, gender or time after transplant influenced long-term immune memory at the distinct compartments, adjusting for the type of COVID-19 clinical severity, given its preponderance leading to distinct long-lasting SARS-CoV-2-specific immune responses.

Contrary to infection severity, age and gender did not impact on long term immunity of IC individuals; (data not shown).

Among SOT, however, in addition to COVID-19 disease severity, time (years) since transplantation was also revealed as an independent factor modulating the maintenance of long-term peripheral immune memory (Supplementary 

In this study, we investigated the persistence and magnitude of adaptive immune Recent studies have shown that for seasonal coronaviruses, protective immunity seems to be predominantly short-lived. 22 However, detectable long-term immune memory against SARS-CoV-2 within three main compartments (serological and B and J o u r n a l P r e -p r o o f T cell memory), has been described in convalescent IC individuals beyond 6 months after COVID-19. 8, 17 In our study, while we confirm that COVID-19 provides detectable peripheral immunity from the more severe to the mild and asymptomatic groups was clearly delineated in our patients. 8, 9, 10, 11, 12 In fact, while more than 80% of severe convalescent COVID-19

subjects were seropositive and displayed robust SARS-CoV-2-specific IgG and cytokine-producing memory B and T cells, respectively, only in 40% were detectable among the asymptomatic group. A potential explanation for these findings may rely in recent observations showing that severe hospitalized cases, both IC and SOT, display higher viral loads, viremia and longer viral shedding as compared to milder COVID-19 cases, 23, 24, 25, 26 which may lead to higher antigen exposure ultimately triggering stronger and long-lasting immune responses.

In line with previous studies, 8, 27 we also found a high correlation between the different immune compartments specific to SARS-CoV-2. However, these differences were predominantly driven by the IC group, suggesting a more impaired functional immune Also, the mild infection group of the study, which was fundamentally based on healthcare workers was a bit younger and were analyzed at a later time. However, in general these differences did not impact on the immune responses compared to the same mild SOT group. While the number of asymptomatic patients was lower than the others two groups, the consistency of the results observed within this group counterbalance this constraint. Finally, we could not describe the predominant T or B cell subsets, responsible of these SARS-CoV-2-reactive T and B cells. However, our

FluoroSpot assay allowed us to functionally assess the frequencies of different IgGand cytokine-producing B and T cells specific to SARS-CoV-2 at the single cell level.

In conclusion, our findings show that robust humoral and cellular immune memory persists among IC and SOT convalescent COVID-19 patients for more than 6 months after infection, and these responses are highly dependent on the clinical degree of COVID-19 severity, which might ultimately illustrate distinct level of viral antigen exposure. However, long-lasting adaptive immunity seems to be challenged to some extent by chronic immunosuppression, especially among those more recently transplanted. Our data may have some relevant implications regarding the long-lasting immune response achieved after vaccination, highlighting the need of an accurate and broader assessment of SARS-CoV-2 immune response to establish guided preventive strategies. Figure 1 . Flow-chart of the study. *p<0.05 (Chi-square Test and T-Test). 

Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

COVID-19 in Spain: Transplantation in the midst of the pandemic

COVID-19 infection in kidney transplant recipients: Disease incidence and clinical outcomes

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

The kinetics of humoral response and its relationship with the disease severity in COVID-19

Delayed production of neutralizing antibodies correlates with fatal COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-)

SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients

The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression

Antibody response to 2-dose sarscov-2 mrna vaccine series in solid organ transplant recipients

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Seasonal coronavirus protective immunity is short-lasting

disease severity and mortality

Viral dynamics in mild and severe cases of COVID-19 The first COVID-19 case in Afghanistan acquired from Iran

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

In-depth virological assessment of kidney transplant recipients with COVID-19

Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection

Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19-recovered patients who received a kidney transplant

Prevalence and predictors of SARS--2 antibodies among solid organ transplant recipients with confirmed infection

Reconciling short-term clinical and immunological outcomes of SARS-CoV-2 vaccination in solid organ transplant recipients

This work was Supported by a national competitive grant by the Instituto de Salud Carlos iii (COV20/00324) and by la Fundació La Marató de TV3 (202101 (64 / 198).We want to acknowledge Biobank HUB-ICO-IDIBELL (PT20/00171) integrated in the Spanish Biobank Network and Xarxa Banc de Tumors de Catalunya (XBTC) for their collaboration.

J o u r n a l P r e -p r o o f